Secure Asset Management LLC Sells 1,139 Shares of Amgen Inc. $AMGN

Secure Asset Management LLC lowered its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 54.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 950 shares of the medical research company’s stock after selling 1,139 shares during the quarter. Secure Asset Management LLC’s holdings in Amgen were worth $344,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in AMGN. Brighton Jones LLC grew its holdings in shares of Amgen by 23.5% during the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after purchasing an additional 5,226 shares in the last quarter. Sivia Capital Partners LLC raised its stake in Amgen by 10.6% in the second quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock valued at $331,000 after purchasing an additional 114 shares in the last quarter. Schnieders Capital Management LLC. raised its stake in Amgen by 29.3% in the second quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock valued at $7,220,000 after purchasing an additional 5,853 shares in the last quarter. Main Street Financial Solutions LLC lifted its position in Amgen by 11.3% during the second quarter. Main Street Financial Solutions LLC now owns 4,086 shares of the medical research company’s stock worth $1,141,000 after purchasing an additional 416 shares during the period. Finally, Ieq Capital LLC grew its stake in Amgen by 5.1% during the second quarter. Ieq Capital LLC now owns 54,152 shares of the medical research company’s stock worth $15,120,000 after buying an additional 2,611 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: New evidence that Amgen’s cholesterol drug Repatha reduced the risk of death among patients at high risk of heart attack or stroke strengthens the drug’s clinical profile and could support broader use, sales growth and reimbursement. Amgen’s Repatha reduces risk of death in people at high risk of heart attack or stroke
• Positive Sentiment: Commentary highlighted Repatha’s potentially significant cardiovascular opportunity, adding to investor enthusiasm about a product that could become an important long-term growth driver beyond Amgen’s current results. Jim Cramer on Amgen’s cardiovascular opportunity
• Positive Sentiment: Analyst H. Engel of Erste Group raised the firm’s 2027 EPS estimate to $24.43 from $23.50, signaling improved expectations for Amgen’s earnings trajectory, although the firm maintained a Hold rating.
• Neutral Sentiment: Amgen will present at the Wells Fargo Healthcare Conference, giving investors a potential update on its pipeline, commercial outlook and strategy. The announcement itself contains no new financial guidance. Amgen to present at the 2026 Wells Fargo Healthcare Conference
• Negative Sentiment: U.K. regulators suspended Tavneos for new patients and halted its sale after determining that the main supporting study contained unreliable data. The action threatens sales of the rare-disease treatment and raises the risk of additional regulatory scrutiny or restrictions in other markets. UK regulator suspends Amgen’s Tavneos for new patients

Insiders Place Their Bets

In other news, SVP Nancy A. Grygiel sold 2,970 shares of the stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the transaction, the senior vice president directly owned 7,340 shares in the company, valued at approximately $2,951,854.40. This represents a 28.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Rachna Khosla sold 2,000 shares of the firm’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total value of $825,140.00. Following the sale, the senior vice president directly owned 6,404 shares in the company, valued at approximately $2,642,098.28. This trade represents a 23.80% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 6,222 shares of company stock valued at $2,540,926 over the last quarter. 0.85% of the stock is owned by corporate insiders.

Amgen Trading Up 1.1%

AMGN opened at $442.84 on Thursday. The company has a market cap of $239.41 billion, a P/E ratio of 27.52, a PEG ratio of 3.16 and a beta of 0.43. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. The company’s 50 day moving average is $393.99 and its 200-day moving average is $366.13. Amgen Inc. has a 1-year low of $269.77 and a 1-year high of $447.03.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.62 by $0.67. The business had revenue of $10.05 billion during the quarter, compared to analysts’ expectations of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The firm’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same period in the prior year, the company earned $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Equities research analysts predict that Amgen Inc. will post 22.97 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be issued a dividend of $2.52 per share. The ex-dividend date is Friday, August 21st. This represents a $10.08 annualized dividend and a dividend yield of 2.3%. Amgen’s dividend payout ratio is 62.65%.

Analyst Upgrades and Downgrades

Several equities analysts have commented on AMGN shares. BMO Capital Markets raised their target price on shares of Amgen from $400.00 to $450.00 and gave the company an “outperform” rating in a report on Wednesday, August 5th. Freedom Capital upgraded shares of Amgen from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. TD Cowen lifted their price objective on shares of Amgen from $420.00 to $452.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Daiwa Securities Group lowered their price objective on shares of Amgen from $410.00 to $390.00 and set an “outperform” rating for the company in a research report on Wednesday, May 13th. Finally, Sanford C. Bernstein upped their target price on Amgen from $335.00 to $345.00 and gave the stock a “market perform” rating in a research note on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, thirteen have given a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $380.43.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.